A small trial helped some people with advanced retinitis pigmentosa sense light

The University of Pittsburgh reported on October 7, 2026, that a study published the same day in the New England Journal of Medicine tested an experimental optogenetic therapy in the PIONEER trial. Surgeons made one injection of a gene for the light-sensing protein ChrimsonR into retinal ganglion cells. The ten participants were legally blind from advanced retinitis pigmentosa and had little or no remaining vision. The protein works only with a camera, a processor, and goggles that project specific light patterns onto the retina.

Most eye-related side effects were mild or moderate, including temporary inflammation and short-lived rises in eye pressure. Seven of the ten people had improved light sensitivity, and six of those gains were large enough to count as clinically meaningful. The treatment did not restore normal vision or the ability to read. Some people could detect an object, tell where it was, and reach for it while wearing the goggles. EEG recordings led by Marlene Behrmann showed signals reaching the visual cortex. Four participants had consistent gains on real-world tasks over months to years of testing.

The trial is early and small. It is not a cure. GenSight Biologics, the company developing the approach, funded the work. Retinitis pigmentosa affects more than 1.5 million people worldwide and can stem from any of more than 100 genes. José-Alain Sahel of Pitt and UPMC is the first and co-corresponding author, with collaborators in Europe.